Related Experiment Video
Updated: May 26, 2026
06:19
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
New and emerging disease modifying therapies for multiple sclerosis
Shiv Saidha1, Christopher Eckstein, Peter A Calabresi
1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Annals of the New York Academy of Sciences
|January 10, 2012
Summary
Newer multiple sclerosis (MS) treatments offer improved efficacy and convenience but carry risks. Neurologists must balance benefits against potential serious adverse events and limited long-term safety data for these disease-modifying drugs (DMDs).
Area of Science:
- Neurology
- Pharmacology
Background:
- Multiple sclerosis (MS) treatment landscape is evolving with new disease-modifying drugs (DMDs).
- Emerging therapies, including oral options, offer enhanced efficacy and convenience over traditional injectables.
Purpose of the Study:
- To review the mechanisms of action, efficacy, and safety profiles of new and emerging MS DMDs.
- To inform neurologists on critical factors for therapeutic decision-making in MS management.
Main Methods:
- Review of current literature on newly approved and investigational MS disease-modifying drugs.
- Analysis of efficacy, convenience, safety, and tolerability data for emerging MS therapies.
Main Results:
- New MS DMDs show promise in efficacy and oral administration.
- Significant concerns exist regarding serious, potentially life-threatening adverse events associated with these novel treatments.
- Limited long-term safety data for many emerging MS therapies necessitates cautious clinical application.
Conclusions:
- Neurologists face complex decisions balancing the advantages of new MS therapies against their safety concerns.
- Careful consideration of efficacy, convenience, and potential risks is crucial for optimizing patient outcomes in multiple sclerosis.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.